Charles Zhou
Stock Analyst at Guggenheim
(1.51)
# 3,457
Out of 5,012 analysts
11
Total ratings
62.5%
Success rate
-1.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $15.44 | +29.53% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $170.93 | -20.44% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $16.50 | -3.03% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.72 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.36 | +4,017.65% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.82 | +2,427.47% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.61 | - | 2 | Jan 22, 2020 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $15.44
Upside: +29.53%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $170.93
Upside: -20.44%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $16.50
Upside: -3.03%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.72
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.36
Upside: +4,017.65%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.82
Upside: +2,427.47%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.61
Upside: -